SPEXIS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.063 CHF | -0.94% |
|
+7.14% | +53.66% |
| May. 01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.69M | - | - | - | - | - | |
| 88.91B | ||||||
| 41.25B | ||||||
| 31.99B | ||||||
| 24.73B | ||||||
| 15.54B |
- Stock Market
- Equities
- SPEX Stock
- Charts Spexis AG
- Sector Chart